{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:47:23Z","timestamp":1780724843486,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clml.2023.12.004","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T09:46:50Z","timestamp":1703756810000},"page":"232-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"24","author":[{"given":"\u00d6zge","family":"S\u00f6nmez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurg\u00fcl","family":"\u00d6zg\u00fcr Yurtta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lker","family":"\u0130htiyaro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-1618","authenticated-orcid":false,"given":"Halil Mete","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Atl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9496-5353","authenticated-orcid":false,"given":"Tu\u011frul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Saliho\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"Seyahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeniz","family":"\u00d6ng\u00f6ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Ba\u015flar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2023.12.004_bib0001","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2023.12.004_bib0002","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2023.12.004_bib0003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.clml.2023.12.004_bib0004","first-page":"7","article-title":"Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission","volume":"10","author":"Serpa","year":"2010","journal-title":"BMC Blood Disord"},{"issue":"1","key":"10.1016\/j.clml.2023.12.004_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/hematology.2021000239","article-title":"Lifelong TKI therapy: how to manage cardiovascular and other risks","volume":"2021","author":"Mauro","year":"2021","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.clml.2023.12.004_bib0006","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2023.12.004_bib0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.clml.2023.12.004_bib0008","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/nep.14014","article-title":"Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients","volume":"27","author":"Singh","year":"2022","journal-title":"Nephrology"},{"issue":"14","key":"10.1016\/j.clml.2023.12.004_bib0009","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2023.12.004_bib0010","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome\u2013positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.12.004_bib0011","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","article-title":"Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients","volume":"22","author":"Marcolino","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.12.004_bib0012","first-page":"IJH38","article-title":"The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"11","author":"Saydam","year":"2021","journal-title":"Future Med"},{"issue":"9","key":"10.1016\/j.clml.2023.12.004_bib0013","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.clml.2023.12.004_bib0014","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.clml.2023.12.004_bib0015","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.clml.2023.12.004_bib0016","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.ki.5002755","article-title":"Age- and gender-specific reference values of estimated glomerular filtration rate in a Caucasian population: results of the Nijmegen biomedical study","volume":"73","author":"Wetzels","year":"2008","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.clml.2023.12.004_bib0017","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00277-018-3375-9","article-title":"Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events","volume":"97","author":"Molica","year":"2018","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.clml.2023.12.004_bib0018","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1002\/cncr.29587","article-title":"Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"121","author":"Yilmaz","year":"2015","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.clml.2023.12.004_bib0019","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1002\/cncr.25071","article-title":"Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and\/or renal dysfunction","volume":"116","author":"Tong","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.12.004_bib0020","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1182\/blood-2018-99-111465","article-title":"Case Report: chronic myeloid leukemia treatment in a hemodialysis patient","volume":"132","author":"Cinarsoy","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.12.004_bib0021","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12185-019-02596-z","article-title":"Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia","volume":"109","author":"Sakurai","year":"2019","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2023.12.004_bib0022","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s12185-022-03433-6","article-title":"Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin\u2013aldosterone\u2013angiotensin system inhibitors in patients with chronic myelogenous leukemia","volume":"116","author":"Tsuda","year":"2022","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2023.12.004_bib0023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12185-016-2071-6","article-title":"Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia","volume":"104","author":"Hino","year":"2016","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2023.12.004_bib0024","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00277-019-03690-2","article-title":"Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors","volume":"98","author":"Ren","year":"2019","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.clml.2023.12.004_bib0025","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","article-title":"Effects of bosutinib treatment on renal function in patients with philadelphia chromosome-positive leukemias","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.12.004_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00883","article-title":"Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia","volume":"10","author":"Annunziata","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.12.004_bib0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-020-02880-3","article-title":"Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors","volume":"112","author":"Okamoto","year":"2020","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.12.004_bib0028","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0002-9440(10)63651-6","article-title":"Activation of src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury","volume":"163","author":"Takikita-Suzuki","year":"2003","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.clml.2023.12.004_bib0029","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)65484-3","article-title":"Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury","volume":"155","author":"Nakagawa","year":"1999","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.clml.2023.12.004_bib0030","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2023.12.004_bib0031","doi-asserted-by":"crossref","unstructured":"Vidal-Petiot E, Rea D, Serrano F, et al. Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2016;16(3):169-74.","DOI":"10.1016\/j.clml.2015.12.001"},{"issue":"12","key":"10.1016\/j.clml.2023.12.004_bib0032","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2169\/internalmedicine.48.2747","article-title":"Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia","volume":"49","author":"Yuzawa","year":"2010","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.clml.2023.12.004_bib0033","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.leukres.2009.07.009","article-title":"Renal failure associated with tyrosine kinase inhibitors: case report and review of the literature","volume":"34","author":"Gafter-Gvili","year":"2010","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T02:13:51Z","timestamp":1712542431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2152265023021936"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}